Trial Profile
Long-term safety and tolerability of dasatinib (BMS-354825) in subjects who experienced clinical benefit on protocol CA 180-002
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 18 Sep 2009 Bristol-Myers Squibb added as a trial sponsor as reported by ClinicalTrials.gov (NCT00978731).
- 18 Sep 2009 Bristol-Myers Squibb added as a trial sponsor as reported by ClinicalTrials.gov (NCT00978731).
- 15 Oct 2006 New trial record.